UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2012
QUESTCOR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| | | | |
| California | | 001-14758 | | 33-0476164 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (I.R.S. Employer
Identification No.) |
| |
1300 Kellogg Drive, Suite D, Anaheim, California | | 92807 |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (714) 786-4200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01. | Regulation FD Disclosure. |
On June 14, 2012, Questcor Pharmaceuticals, Inc. (the “Company”) issued a press release providing information on its commercialization strategy for H.P. Acthar® Gel (repository corticotropin injection) (“Acthar”) for the following rheumatology-related FDA-approved indications on the label for Acthar:
| | • | | Collagen Diseases: “during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis).” |
| | • | | Rheumatic Disorders: “as adjunctive therapy for short-term administrative (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis.” |
A copy of the Company’s press release is attached hereto as Exhibit 99.1, and incorporated herein by reference.
Also on June 14, 2012, the Company held a conference call with analysts and investors, the presentation slides and transcript of which are filed as Exhibit 99.2 and 99.3, respectively, and both of which are incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, 99.2 and 99.3, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| | |
| Exhibit Number | | Description |
| |
| 99.1 | | Questcor Pharmaceuticals, Inc. press release dated June 14, 2012. |
| |
| 99.2 | | Presentation slides used during conference call held on June 14, 2012. |
| |
| 99.3 | | Transcript of conference call held on June 14, 2012 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| Date: June 19, 2012 | | QUESTCOR PHARMACEUTICALS, INC. |
| | |
| | By: | | /s/ Michael H. Mulroy |
| | | | Michael H. Mulroy, Chief Financial |
| | | | Officer and General Counsel |
3
EXHIBIT INDEX
| | | | |
Exhibit No. | | Description |
| |
| 99.1 | | Questcor Pharmaceuticals, Inc. press release dated June 14, 2012. |
| |
| 99.2 | | Presentation slides used during conference call held on June 14, 2012. |
| |
| 99.3 | | Transcript of conference call held on June 14, 2012 |
4
